Ube Industries, Inc.

Sanwa Kagaku Kenkyusho Co., Ltd.

Other

Sankyo Company, Limited

Ryo Iwamura

Masayuki Tanaka

Tomio Kimura

Hiroyuki Koike

Masahiko Hagihara

Teruhiko Inoue

Fumitoshi Asai

Atsuhiro Sugidachi

Yasunori Tsuzaki

Hiroyuki Setoguchi

Toshihiko Ikeda

Hiroto Akaza

Motohisa Shimizu

Yasuhito Yamamoto

Hiroshi Fujiwara

Tetsushi Katsube

Haruo Iwabuchi

Eiji Okanari

Yoshiaki Kuroki

Katsunori Takata

Nobuhiko Shibakawa

Yasunori Tokunaga

Akira Takama

Kenji Yoneda

Jun-ichiro Kita

Manabu Shigetomi

Kaori Taniko

Toshiyuki Miyazawa

Daisuke Kurumazuka

Satoko Harada

Toru Izuchi

Morio Okabe

Yuka Kuno

Tatsuroh Kaneko

Yuuki Imura

Kurumazuka Daisuke

Kaneko Tatsuroh

Miyazawa Toshiyuki

Taniko Kaori

Harada Satoko

Izuchi Toru

Okabe Morio

Yoko Murakami

Disclosed herein are a crystal comprising a compound, which has &#x3bc;-opioid receptor antagonistic action, few side effects, and high safety, and having high purity and excellent physical properties (stability, solubility, etc.), and a method for producing the crystal. The crystal is a crystal of a salt comprising: a compound represented by a formula (I) [wherein Ris a hydrogen atom or a halogen atom, and Ris a group selected from the group consisting of and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, and oxalic acid, or a hydrate thereof.

Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof

The object of the present invention is to provide a compound having an antagonistic action against &#x3bc;-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof:   

3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R, R, R, Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.

Pyridylaminoacetic acid compound

Cyclic amino compounds

A cyclic amine derivative represented by the following formula: ##STR1## wherein R.sup.1 represents a substituted or unsubstituted phenyl group, R.sup.2 represents a substituted of unsubstituted C.sub.1 -C.sub.8 aliphatic acyl group, a substituted or unsubstituted benzoyl group or a C.sub.1 -C.sub.4 alkoxycarbonyl group, and R.sup.3 represents a substituted 3 to 7 membered saturated cyclic amino group which may form a fused ring; or pharmaceutically acceptable salts thereof. The compounds and salts have excellent platelet aggregation inhibitory action. They are useful for the treatment and prevention of such diseases as embolism, thrombosis or arteriosclerosis and for the preparation of pharmaceutical compositions for such uses.

Cyclic amine derivatives

Growing community of inventors

Ube, Japan

Ryo Iwamura